Abstract
Background
Evaluation of symptom presentation and antipsychotic response based on ethnicity in children and adolescents with schizophrenia is limited. The purpose of this naturalistic, retrospective database study was to compare symptom presentation of children and adolescents of different ethnicities with schizophrenia-spectrum disorders, and response to risperidone.
Method
African-American (n = 38), Caucasian (n = 30), or Hispanic (n = 37) youths started on risperidone were eligible. Child Behavior Checklist (CBCL) total, internalizing, and externalizing scores were evaluated at baseline, 90 days, 1 year, and 2 year intervals.
Results
At baseline, Hispanic patients had lower CBCL externalizing scores than African-Americans or Caucasians. African-Americans showed significant differences in CBCL total, internalizing, and externalizing scores at 90 days compared to baseline. Hispanics showed improvement in CBCL internalizing scores over the 2 year period. No significant improvements were observed in Caucasians. African-American patients had significantly lower CBCL total at 90 days compared to Hispanic patients. No significant difference existed in 2 year hospitalization rates between groups.
Conclusions
These findings suggest that ethnicity may play a role in symptom presentation and treatment response to risperidone for children and adolescents with schizophrenia-spectrum disorders. Future studies in children and adolescents are necessary to examine ethnospecific differences in antipsychotic use and treatment response.
Similar content being viewed by others
References
Fabrega H, Mezzich J, Ulrich JF (1988) African-American – White differences in psychopathology in an urban psychiatric population. Compr Psychiatry 29:285–297
Brekke JS, Barrio C (1997) Cross-ethnic symptom differences in schizophrenia: the influence of culture and minority status. Schizophr Bull 23:305–316
Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, Russo PA (2003) A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. Schizophr Res 60:259–269
Weisman AG, Lopez SR, Ventura J, Nuechterlein KH, Goldstein MJ, Hwang S (2000) A comparison of psychiatric symptoms between Anglo-Americans and Mexican-Americans with schizophrenia. Schizophr Bull 26:817–824
Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R (1986) Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med 16:909–928
Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31:1360–1369
Collazo J, Tam R, Sramek JJ, Herrera J (1996) Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med 63:310–313
Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, Niehaus DJH, Keyter N, Stein DJ (2002) Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 63:9–14
American Academy of Child, Adolescent Psychiatry (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 40(suppl 7):4S–23S
Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J (1997) Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36:694–700
Quintana H, Keshavan M (1995) Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 34:1292–1296
Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC (1996) Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 6:251–257
Achenbach TM (2000) Child behavior checklists (CBCL/2-3 and CBCL/4-18), Teacher report form (TRF), and Youth self report (YSR). In: Handbook of psychiatric measures. American Psychiatric Association, Washington DC, pp 310–314
Kopelowicz A, Zarate R, Gonzales V, Lopez SR, Ortega P, Obregon N, Mintz J (2002) Evaluation of expressed emotion in schizophrenia: a comparison of Caucasians and Mexican-Americans. Schizophr Res 55:179–186
Frackiewicz EJ, Herrera JM, Sramek JJ, Collazo Y, Lawson WB (2002) Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. Psychiatry 65:371–374
Lasser KE, Himmelstein DU, Woolhandler SJ, McCormick D, Bor DH (2002) Do minorities in the United States receive fewer mental health services than whites? Int J Health Serv 32:567–578
Cauce AM, Domenech-Rodriguez M, Paradise M, Cochran BN, Shea JM, Srebnik D, Baydar N (2002) Cultural and contextual influences in mental help seeking: a focus on ethnic minority youth. J Consult Clin Psychol 70:44–55
Fields JH, Grochowski S, Lindenmayer JP, Kay SR, Grosz D, Hyman RB, Alexander G (1994) Assessing positive and negative symptoms in children and adolescents. Am J Psychiatry 151:249–253
Stratkowski SM, Keck PE, Arnold LM, Collins J, Wilson RM, Fleck DE, Corey KB, Amicone J, Adebimpe VR (2003) Ethnicity and diagnosis in patients with affective disorders. J Clin Psychiatry 64:747–754
Fleischhacker WW, Oehl MA, Hummer M (2003) Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64(suppl 16):10–13
Opolka JL, Rascati KL, Brown CM, Gibson PJ (2003) Role of ethnicity in predicting antipsychotic medication adherence Ann Pharmacother 37:625–630
Author information
Authors and Affiliations
Corresponding author
Additional information
Location of work: College of Pharmacy, The University of Texas at Austin, TX; Austin State Hospital, Austin, TX; and, Texas Department of State Health Services, Austin, TX.
Supported in part by a Ruth L. Kirschstein NRSA Fellowship sponsored by NIMH (N. Patel) and the Texas Department of State Health Services.
Rights and permissions
About this article
Cite this article
Patel, N.C., Crismon, M.L., Shafer, A. et al. Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. Soc Psychiat Epidemiol 41, 341–346 (2006). https://doi.org/10.1007/s00127-006-0036-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00127-006-0036-4